280 related articles for article (PubMed ID: 37753925)
1. Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice.
Camilleri M; Lupianez-Merly C
Am J Gastroenterol; 2024 Jun; 119(6):1028-1037. PubMed ID: 37753925
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
3. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
4. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
5. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
[TBL] [Abstract][Full Text] [Related]
6. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
Mathiesen DS; Bagger JI; Bergmann NC; Lund A; Christensen MB; Vilsbøll T; Knop FK
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443356
[TBL] [Abstract][Full Text] [Related]
9. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
10. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
Madsbad S
Diabetes Obes Metab; 2014 Jan; 16(1):9-21. PubMed ID: 23617798
[TBL] [Abstract][Full Text] [Related]
11. Newer pharmacological interventions directed at gut hormones for obesity.
Camilleri M; Acosta A
Br J Pharmacol; 2024 Apr; 181(8):1153-1164. PubMed ID: 37917871
[TBL] [Abstract][Full Text] [Related]
12. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
Holst JJ; Rosenkilde MM
J Clin Endocrinol Metab; 2020 Aug; 105(8):e2710-6. PubMed ID: 32459834
[TBL] [Abstract][Full Text] [Related]
13. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
14. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
15. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Rohde U
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
[TBL] [Abstract][Full Text] [Related]
16. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
17. Targeted intestinal delivery of incretin secretagogues-towards new diabetes and obesity therapies.
Gribble FM; Meek CL; Reimann F
Peptides; 2018 Feb; 100():68-74. PubMed ID: 29412834
[TBL] [Abstract][Full Text] [Related]
18. Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
Stensen S; Krogh LL; Sparre-Ulrich AH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Gasbjerg LS; Knop FK
Diabetes Obes Metab; 2022 Sep; 24(9):1882-1887. PubMed ID: 35491518
[No Abstract] [Full Text] [Related]
19. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
20. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
